Skip to main content
Daniel Mandri, MD, Psychiatry, Miami, FL

DanielFMandriMD

Psychiatry Miami, FL

Physician

Dr. Mandri is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Mandri's full profile

Already have an account?

  • Office

    8785 SW 165th Ave
    Ste 200
    Miami, FL 33193
    Phone+1 786-554-0008
    Fax+1 786-209-2160

Education & Training

  • University of Miami/Jackson Health System
    University of Miami/Jackson Health SystemResidency, Psychiatry, 1980 - 1983
  • Advocate Health Care/Advocate Christ Medical Center
    Advocate Health Care/Advocate Christ Medical CenterInternship, Internal Medicine, 1979 - 1980
  • Universidad Central del Este Facultad de Medicina
    Universidad Central del Este Facultad de MedicinaClass of 1977

Certifications & Licensure

  • FL State Medical License
    FL State Medical License 1979 - 2026
  • American Board of Psychiatry and Neurology Psychiatry

Awards, Honors, & Recognition

  • Physician's Recognition Award American Medical Association
  • Certificate of Commendation Mental Health Association of Dade County
  • Certificate of Appreciation for Exemplary Service Admission Committee Herbert. Wertheim College of Medicine Florida International University

Publications & Presentations

PubMed

Research History

  • Principal investigatorProtocol xxxxx: A study to assess effectiveness, safety and health related outcomes of xxxxx for the treatment of Pseudobulbar affect in nursing home patients.
  • Principal InvestigatorProtocol xxxxx: A phase III, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of xxxxx for the treatment of agitation in patients with dementia of the Alzheimer’s type.
  • Principal investigatorProtocol xxxxx: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel, Fixed-Dose Study to Assess the Efficacy, Safety, and Tolerability of xxxxx for the Treatment of Tardive Dyskinesia.

Professional Memberships

  • American Psychiatric Association
    Fellow
  • The New York Academy of Science
    Member
  • The Royal Society of Medicine
    Member
  • World Psychiatric Association
    Member

Other Languages

  • Spanish